Evaluation of chios mastic gum on lipid and glucose metabolism in diabetic mice

Journal of Medicinal Food

Volumn 17, Issue 3, 2014, Pages 393-399

  Georgiadis, Ioannis ^a   Karatzas, Theodore ^a,b   Korou, Laskarina Maria ^a   Agrogiannis, George ^a   Vlachos, Ioannis S ^a   Pantopoulou, Alkisti ^a   Tzanetakou, Irene P ^a   Katsilambros, Nikolaos ^a   Perrea, Despina N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chios mastic gum; diabetes; dietary herbal supplement; hepatoprotection; lipid metabolism; mice

Indexed keywords

ADIPONECTIN; CHIO MASTIC GUM; CHOLESTEROL; GLUCOSE; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIET SUPPLEMENTATION; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART INJURY; HISTOPATHOLOGY; KIDNEY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PISTACIA LENTISCUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS; GLUCOSE; HUMANS; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; PISTACIA; PLANT EXTRACTS; RESINS, PLANT;

EID: 84896974451     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.0069     Document Type: Article

References (31)

1. Moussaieff A, Fride E, Amar Z, Lev E, Steinberg D, Gallily R, Mechoulam R: The Jerusalem Balsam: from the Franciscan Monastery in the old city of Jerusalem to Martindale 33. J Eth-nopharmacol 2005;101:16-26.
2. Kolliaros G: Chios Mastic. Chios mastic from antiquity to today. In: Tradition and Current Practice. Acta of the International Symposium held in Chios on October 3-5, 1997; Athens, Greece, 1997, pp. 242-243.
3. Triantafyllou A, Bikineyeva A, Dikalova A, Nazarewicz R, Lerakis S, Dikalov S: Anti-inflammatory activity of Chios mastic gum is associated with inhibition of TNF-alpha induced oxida-tive stress. Nutr J 2011;10:64.
4. Triantafyllou A, Chaviaras N, Sergentanis TN, Protopapa E, Tsaknis J: Chios mastic gum modulates serum biochemical parameters in a human population. J Ethnopharmacol 2007;111: 43-49.
5. Marone P, Bono L, Leone E, Bona S, Carretto E, Perversi L: Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J Chemother 2001;13:611-614.
6. Huwez FU, Thirlwell D, Cockayne A, Ala'Aldeen DA: Mastic gum kills Helicobacter pylori. N Engl J Med 1998;339:1946.
7. Loughlin MF, Ala'Aldeen DA, Jenks PJ: Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice. J Antimicrob Chemother 2003;51:367-371.
8. Dimas KS, Pantazis P, Ramanujam R: Review: Chios mastic gum: a plant-produced resin exhibiting numerous diverse pharmaceutical and biomedical properties. In Vivo 2012;26:777-785.
9. Koutsoudaki C, Krsek M, Rodger A: Chemical composition andantibacterial activity of the essential oil and the gum of Pis-tacia lentiscus Var. chia. J Agric Food Chem 2005;53:7681-7685.
10. Assimopoulou AN, Papageorgiou VP: GC-MS analysis of penta-and tetra-cyclic triterpenes from resins of Pistacia species. Part I. Pistacia lentiscus var. chia. Biomed Chromatogr 2005;19:285-311.
11. Sanz MJ, Terencio MC, Paya M: Isolation and hypotensive activity of a polymeric procyanidin fraction from Pistacia lentiscus L. Pharmazie 1992;47:466-467.
12. Magiatis P, Melliou E, Skaltsounis AL, Chinou IB, Mitaku S: Chemical composition and antimicrobial activity of the essential oils of Pistacia lentiscus var. Chia. Planta Medica 1999;65:749-752.
13. Petersen RK, Christensen KB, Assimopoulou AN, Fretté X, Pa-pageorgiou VP, Kristiansen K, Kouskoumvekaki I: Pharmaco-phore-driven identification of PPARc agonists from natural sources. J Comput Aided Mol Des 2011;25:107-116.
14. Vallianou I, Peroulis N, Pantazis P, Hadzopoulou-Cladaras M: Camphene, a plant-derived monoterpene, reduces plasma cholesterol and triglycerides in hyperlipidemic rats independently of HMG-CoA reductase activity. PLoS One 2011;6:e20516.
15. Korou LM, Agrogiannis G, Pantopoulou A, Vlachos IS, Ilio-poulos D, Karatzas T, Perrea DN: Comparative antilipidemic effect of N-acetylcysteine and sesame oil administration in diet-induced hypercholesterolemic mice. Lipids Health Dis 2010;9:23.
16. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
17. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, Winegar DA, Strum JC, Stimpson SA, Pahel GL: Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitiza-tion/lipid lowering in rats. BMC Pharmacol 2004;4:23.
18. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
19. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117: 2621-2637.
20. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA: Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol En-docrinol Metab 2006;290:E42-E46.
21. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ: Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006;291:E1100-E1105.
22. Carbone F, La Rocca C, Matarese G: Immunological functions of leptin and adiponectin. Biochimie 2012;94:2082-2088.
23. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003;52:1779-1785.
24. Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007;18: 263-270.
25. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20: 649-688.
26. Schoonjans K, Auwerx J: Thiazolidinediones: an update. Lancet 2000;355:1008-1010.
27. Paraschos S, Mitakou S, Skaltsounis AL: Chios gum mastic: a review of its biological activities. Curr Med Chem 2012;19: 2292-2302.
28. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E: Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010;53:713-718.
29. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastro-enterol Hepatol 2008;23:102-109.
30. Zadik H: Therapeutic uses of mastic gum fractions. Australia. Patent AU2010220056. March 4, 2010.
31. Moulos P, Papadodima O, Chatziioannou A, Loutrari H, Roussos C, Kolisis FN: A transcriptomic computational analysis of mastic oil-treated Lewis lung carcinomas reveals molecular mechanisms targeting tumor cell growth and survival. BMC Med Genomics 2009;2:68.